Knight Therapeutics Inc.
GUD.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.88% | 11.33% | 4.36% | 5.19% | -9.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.88% | 11.33% | 4.36% | 5.19% | -9.34% |
| Cost of Revenue | 37.37% | 12.45% | -9.65% | 7.68% | -10.89% |
| Gross Profit | 14.62% | 10.17% | 23.95% | 2.63% | -7.46% |
| SG&A Expenses | 30.02% | 8.93% | 13.22% | 17.66% | -23.67% |
| Depreciation & Amortization | -7.05% | -4.24% | 1.66% | -2.36% | -35.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.61% | 8.70% | -0.67% | 9.42% | -18.38% |
| Operating Income | -3,366.39% | 238.68% | 4,110.01% | -52.63% | 99.09% |
| Income Before Tax | 129.27% | -93.28% | 230.23% | -44.90% | -12.78% |
| Income Tax Expenses | -52.22% | 174.55% | 260.10% | -158.31% | 77.08% |
| Earnings from Continuing Operations | 142.89% | -99.13% | -203.61% | -15.84% | -59.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 142.89% | -99.13% | -203.61% | -15.84% | -59.80% |
| EBIT | -3,366.39% | 238.68% | 4,110.01% | -52.63% | 99.09% |
| EBITDA | -20.19% | 11.55% | 43.93% | -18.30% | 21.46% |
| EPS Basic | 144.26% | -99.11% | -211.11% | -27.59% | -79.96% |
| Normalized Basic EPS | 645.79% | -107.27% | -106.67% | -13.67% | 133.86% |
| EPS Diluted | 140.76% | -99.11% | -215.87% | -12.50% | -83.61% |
| Normalized Diluted EPS | 642.99% | -107.27% | -106.67% | -13.67% | 133.86% |
| Average Basic Shares Outstanding | -3.07% | -4.82% | -6.59% | -9.28% | -11.22% |
| Average Diluted Shares Outstanding | -2.68% | -5.05% | -6.76% | -9.28% | -11.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |